MicroPort CardioFlow Completes Share Consolidation After Conditions Met

The latest update is out from MicroPort CardioFlow Medtech Corp. ( (HK:2160) ).

MicroPort CardioFlow Medtech Corporation has confirmed that its previously proposed share consolidation has become effective as of February 24, 2026, after all required conditions were satisfied. The move follows shareholder approval at an extraordinary general meeting and related announcements detailing the timetable and implementation steps.

The effective share consolidation is expected to streamline the company’s capital structure and may improve the trading characteristics of its stock, such as share price level and market perception. Investors are directed to existing corporate materials for specifics on trading arrangements, free exchange of share certificates and handling of odd lots arising from the consolidation.

The board, led by chairman Chen Guoming and comprising executive, non-executive and independent non-executive directors, formally endorsed the completion of the consolidation. This governance structure underscores that the capital change has been implemented under the supervision of a diversified board, signaling orderly execution of the company’s corporate actions to stakeholders.

The most recent analyst rating on (HK:2160) stock is a Sell with a HK$0.74 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.

More about MicroPort CardioFlow Medtech Corp.

MicroPort CardioFlow Medtech Corporation is a Hong Kong-listed medical technology company focused on cardiovascular interventions. It develops and commercializes devices and solutions for cardiac and vascular procedures, targeting the growing market for minimally invasive heart therapies in China and internationally.

Average Trading Volume: 7,263,473

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.41B

For detailed information about 2160 stock, go to TipRanks’ Stock Analysis page.